NCT07209189 2026-03-09
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
Clinical Trials
10 trialsNCT02994069 2025-10-14
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Phase 2 Active not recruiting
NCT06814158 2025-02-07
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT03067610 2022-03-17
INFIELD
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00833261 2020-08-21
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01362127 2020-02-26
NeoRes
Karolinska University Hospital
Phase 2 Completed
NCT03985670 2019-12-12
Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03579004 2018-07-06
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
Russian Academy of Medical Sciences
Phase 2 Unknown
NCT00547157 2017-03-15
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed
NCT00130780 2016-01-25
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Memorial Sloan Kettering Cancer Center
Phase 2 Completed